A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:November 3, 2011Completed
Hide Studies Not Open or Pending
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:November 3, 2011Completed
Condition(s):Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia in RemissionLast Updated:May 14, 2020Terminated
Condition(s):Myelodysplastic SyndromeLast Updated:May 11, 2016Unknown status
Condition(s):Myelodysplastic SyndromesLast Updated:February 23, 2024Completed
Condition(s):Indolent Non Hodgkin LymphomaLast Updated:April 12, 2013Unknown status
Condition(s):Follicular Lymphoma and Marginal Zone LymphomaLast Updated:October 23, 2023Recruiting
Condition(s):Multiple MyelomaLast Updated:April 14, 2021Completed
Condition(s):Chronic Lymphocytic LeukemiaLast Updated:May 3, 2017Completed
Condition(s):Multiple MyelomaLast Updated:February 25, 2016Completed
Condition(s):Chronic Lymphocytic Leukemia; Small Lymphocytic LeukemiaLast Updated:May 27, 2016Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.